HRG-β3 inhibitors are a class of compounds designed to specifically target and inhibit the activity of HRG-β3, a member of the heregulin family of proteins. HRG-β3 (heregulin-β3) is one of several isoforms of the heregulin protein family that plays a crucial role in various cellular signaling pathways. These inhibitors work by binding to HRG-β3 and preventing its interaction with receptors such as ErbB3 and ErbB4, which are part of the ErbB receptor family. By interfering with HRG-β3's ability to engage with its target receptors, the inhibitors modulate the downstream signaling cascades that are typically triggered by HRG-β3's activity, affecting cellular processes such as growth, differentiation, and intracellular communication.
HRG-β3 inhibitors can vary widely depending on their chemical makeup, but they generally possess moieties that enable selective binding to HRG-β3. These compounds are often designed with high specificity for HRG-β3 to minimize off-target effects on other proteins. The design of HRG-β3 inhibitors is guided by structural biology, which allows for precise interactions at the molecular level, ensuring that the binding affinity is strong enough to effectively block HRG-β3 function. HRG-β3 inhibitors may be synthesized using organic chemistry techniques or discovered through high-throughput screening of chemical libraries. Their development involves fine-tuning molecular features such as hydrophobicity, charge distribution, and molecular size to optimize their performance in biochemical environments.
| Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
|---|---|---|---|---|---|---|
Telmisartan | 144701-48-4 | sc-204907 sc-204907A | 50 mg 100 mg | ¥801.00 ¥1038.00 | 8 | |
Antagonista de los receptores de la angiotensina II, podría influir en la función vascular y en las vías de señalización relacionadas. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | ¥1433.00 | 18 | |
Otro antagonista de los receptores de la angiotensina II, que puede afectar a la presión arterial y a la angiogénesis. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | ¥2843.00 ¥5585.00 | 9 | |
Inhibe la HMG-CoA reductasa, influyendo potencialmente en los niveles de colesterol y en la señalización celular relacionada con la inflamación y la angiogénesis. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | ¥2031.00 ¥3554.00 | 2 | |
Inhibe múltiples tirosina quinasas implicadas en la angiogénesis, afectando potencialmente a procesos en los que la HRG-β3 podría estar implicada. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | ¥1230.00 ¥3949.00 | 8 | |
Modula las respuestas inmunitarias e inhibe la angiogénesis, lo que podría influir en las vías relacionadas con HRG-β3. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | ¥632.00 ¥2933.00 ¥4693.00 | 129 | |
Inhibe las quinasas RAF y otros receptores, podría afectar a la proliferación celular y la angiogénesis. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | ¥869.00 | 2 | |
Activa la AMPK, influyendo potencialmente en las vías metabólicas y el crecimiento celular relacionados con la HRG-β3. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | ¥1726.00 | 5 | |
Inhibe la tirosina quinasa de Bruton, podría afectar a la señalización de las células B y a las respuestas inmunitarias. | ||||||